Overview

Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer

Status:
RECRUITING

Trial end date:
2029-09-01

Target enrollment:

Participant gender:

Summary

This is a Phase 2, multicenter, open-label, single-arm study to evaluate the efficacy and safety of sapanisertib and serabelisib (PIKTOR) with paclitaxel in participants with advanced or recurrent endometrial cancer.

Phase:

PHASE2

Details

Lead Sponsor:

Faeth Therapeutics

Collaborator:

GOG Foundation

Treatments:

Paclitaxel
sapanisertib
serabelisib